We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WW:NASDAQWW International, Inc. Analysis

Data as of 2026-05-11 - not real-time

$10.20

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

WW International is trading at $10.2, well below its 20‑day SMA of 10.37, 50‑day SMA of 14.80 and 200‑day SMA of 25.27, indicating a bearish price trend despite a modestly bullish MACD crossover (MACD line above signal) and an RSI around 42 that suggests no extreme overbought/oversold condition. Valuation metrics are strikingly low: a trailing P/E of 1.55 versus an industry average of 26.45, a price‑to‑book of 0.32 and analyst median target of $30 imply substantial upside potential, while the DCF‑derived fair value of $0.89 raises a question of model sensitivity. Fundamentally, the company faces challenges—revenue has contracted 11.7% YoY, operating margin is negative, and operating cash flow is -$28.9 M, yet gross margins remain healthy at 71.7% and free cash flow is positive at $23.8 M. The balance sheet is leveraged, with total debt of $468 M and a debt‑to‑equity ratio of 147%, but cash holdings of $160 M provide a modest cushion.
The stock exhibits extreme volatility (128% 30‑day) and a high beta of 2.13, signaling sensitivity to market swings, while liquidity is acceptable for a $102 M market‑cap company with rising volume. Given the mix of deep value indicators, operational headwinds, and a strategic shift toward digital subscriptions and GLP‑1‑related services, WW presents a nuanced risk‑reward profile that leans toward a longer‑term upside thesis despite short‑term technical weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below key moving averages signaling bearish momentum
  • High volatility and beta increasing market‑risk exposure
  • Bullish MACD histogram suggesting possible short‑term reversal

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Extremely low P/E and P/B relative to peers
  • Analyst median price target of $30 indicating >180% upside
  • Positive free cash flow and strong gross margins supporting profitability

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic shift to digital subscription and GLP‑1 medication services
  • Undervalued balance‑sheet metrics despite high leverage
  • Long‑term industry tailwinds in weight‑management and health‑tech

Key Metrics & Analysis

Financial Health

Revenue Growth-11.70%
Profit Margin148.60%
P/E Ratio1.6
ROA6.74%
Debt/Equity147.33
P/B Ratio0.3
Op. Cash Flow$-28897000
Free Cash Flow$23.8M
Industry P/E26.4

Technical Analysis

TrendBearish
RSI42.0
Support$8.36
Resistance$12.20
MA 20$10.37
MA 50$14.80
MA 200$25.27
MACDBullish
VolumeIncreasing
Fear & Greed Index90.73

Valuation

Fair Value$0.89
Target Price$28.33
Upside/Downside177.78%
GradeUndervalued
TypeValue

Risk Assessment

Beta2.13
Volatility128.20%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.